82
Participants
Start Date
December 23, 2020
Primary Completion Date
February 2, 2024
Study Completion Date
February 2, 2024
Atezolizumab 1200 mg/m2
Fixed dose of 1200 mg/m2 by intravenous (IV) infusion on D1 of each cycle up to disease progression, unacceptable toxicity or absence of clinical benefit.
Gemcitabine 1000 mg/m2
Gemcitabine 1000 mg/m2 IV on D1 and 1000 mg/m2 IV on D8 of each 21-day cycle for up to 6 cycles.
Cisplatin 70 mg/m2
Cisplatin 70 mg/m2 by IV on split-dose schedule of 35 mg/m2 on day 1 (D1) and 35 mg/m2 on day 8 (D8) for up to 6 cycles.
Hospital Provincial de Castellón, Castellon
Hospital Clínico Universitario San Carlos, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario La Paz, Madrid
Hospital Universitario Central de Asturias, Oviedo
Complejo Hospitalario Universitario Insular Marterno Infantil, Las Palmas de Gran Canaria
Hospital de la Santa Creu i Sant Pau, Barcelona
ICO Hospitalet- Hospital Duran i Reynals, Barcelona
Hospital Universitario de Jaén, Jaén
Complejo Hospitalario Universitario Ourense, Ourense
Hospital Virgen de la Salud, Toledo
Hospital Son Llàtzer, Palma de Mallorca
Roche Farma, S.A
INDUSTRY
Spanish Oncology Genito-Urinary Group
OTHER